<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01555463</url>
  </required_header>
  <id_info>
    <org_study_id>16080</org_study_id>
    <secondary_id>1401846</secondary_id>
    <nct_id>NCT01555463</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea</brief_title>
  <official_title>A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-group Clinical Trial to Assess the Safety and Efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily for 12 Weeks in Subjects With Papulopustular Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of azelaic acid (AzA) foam,
      15% topically applied twice daily for 12 weeks in subjects with papulopustular rosacea
      compared to its vehicle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the efficacy of AzA foam, 15% compared to vehicle topically applied twice daily
      in papulopustular rosacea evaluated by therapeutic success rate according to Investigators
      Global Assessment (IGA) and change in inflammatory lesion count from baseline to end of
      treatment.

      Evaluation of all adverse events will be covered in Adverse Events section.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at End of Treatment (LOCF: Last Observation Carried Forward)</measure>
    <time_frame>At end of treatment (LOCF), up to 12 weeks</time_frame>
    <description>Static evaluation of overall severity of papulopustular rosacea at a given time: 1) Clear: no papules and/or pustules; no erythema; 2) Minimal: rare papules and/or pustules; faint up to but not including mild erythema; 3) Mild: few papules and/or pustules; mild erythema; 4) Moderate: pronounced number of papules and/or pustules (but less than numerous papules and/or pustules); moderate erythema; 5) Severe: numerous papules and/or pustules, occasionally with confluent areas of inflamed lesions; moderate to severe erythema. Therapeutic success is defined as an IGA score of clear or minimal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nominal Change From Baseline in Inflammatory Lesion (IL) Count at End of Treatment (LOCF)</measure>
    <time_frame>Baseline and end of treatment (LOCF), up to 12 weeks</time_frame>
    <description>The mean (standard deviation) change from baseline in the inflammatory lesion count at the end of treatment is provided.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Inflammatory Lesion Count at End of Treatment (LOCF)</measure>
    <time_frame>Baseline and end of treatment (LOCF), up to 12 weeks</time_frame>
    <description>The mean (standard deviation) percentage change in inflammatory lesion count from baseline to end of study is provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Response at End of Treatment (LOCF)</measure>
    <time_frame>At end of treatment (LOCF), up to 12 weeks</time_frame>
    <description>Participants achieving a clear, minimal, or mild IGA at the end of treatment were considered as 'responder'. Participants with an IGA of moderate or severe at the end of treatment were considered as 'non-responder'. Participants who prematurely withdraw from study treatment because of lack of efficacy were coded as 'non-responders'. The percentage of responders is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grouped Changes From Baseline in Erythema Intensity Score at End of Treatment (LOCF)</measure>
    <time_frame>Baseline and end of treatment (LOCF), up to 12 weeks</time_frame>
    <description>Erythema was rated as: clear or almost clear; mild; moderate; or severe. For the assessment of the grouped change in erythema ratings, the baseline examination was used to group into 'improved', 'no change', or 'worsened'. A participant was considered to have an 'improved' erythema rating if the erythema rating was lower compared to the baseline rating, 'no change' if the rating was identical, and 'worsened' if the rating was higher. The percentage of participants in each of these categories is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Investigator's Global Assessment (IGA) Scores at End of Treatment (LOCF)</measure>
    <time_frame>At end of treatment (LOCF), up to 12 weeks</time_frame>
    <description>The IGA consists of 5 scores: 1) Clear: no papules and/or pustules; no erythema; 2) Minimal: rare papules and/or pustules; faint up to but not including mild erythema; 3) Mild: few papules and/or pustules; mild erythema; 4) Moderate: pronounced number of papules and/or pustules (but less than numerous papules and/or pustules); moderate erythema; 5) Severe: numerous papules and/or pustules, occasionally with confluent areas of inflamed lesions; moderate to severe erythema. The percentage of participants with each score at the end of treatment is provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nominal Value of Inflammatory Lesion Count at End of Treatment (LOCF)</measure>
    <time_frame>At end of treatment (LOCF), up to 12 weeks</time_frame>
    <description>The mean (standard deviation) lesion count at the end of treatment is provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Erythema Intensity Score at End of Treatment (LOCF)</measure>
    <time_frame>At end of treatment (LOCF), up to 12 weeks</time_frame>
    <description>The percentage of participants in each rating category of erythema (clear or almost clear; mild; moderate; severe) at the end of treatment is provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grouped Changes From Baseline in Telangiectasia Intensity Score at End of Treatment (LOCF)</measure>
    <time_frame>Baseline and end of treatment (LOCF), up to 12 weeks</time_frame>
    <description>Telangiectasia was rated as: no; mild; moderate; or severe. At the end of study, a participant was considered to have an 'improved' telangiectasia rating if the telangiectasia rating was lower compared to the baseline rating, 'no change' if the rating was identical, and 'worsened' if the rating was higher. The percentage of participants in each category is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Facial Skin Color Rating at End of Treatment (LOCF)</measure>
    <time_frame>At end of treatment (LOCF), up to 12 weeks</time_frame>
    <description>Facial skin color (as compared with skin outside the treatment area) was rated as: normal; barely visible skin lightening; mild skin lightening; moderate skin lightening; severe skin lightening. The percentage of participants in each category of facial skin color at the end of study is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants' Global Assessment of Treatment Response at End of Treatment</measure>
    <time_frame>At end of treatment, up to 12 weeks</time_frame>
    <description>At the end of treatment, participants assessed the change of papulopustular rosacea from baseline (how it looked, felt, appeared to others) as excellent improvement, good improvement, fair improvement, no improvement, or worse. The number of participants in each category of this assessment is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants' Global Assessment of Tolerability at End of Treatment</measure>
    <time_frame>At end of treatment, up to 12 weeks</time_frame>
    <description>At the end of treatment, participants provided their opinion on local tolerability of the investigational product as excellent, good, acceptable despite minor irritation, less acceptable due to continuous irritation, non-acceptable, or no opinion. The number of participants in each category of this assessment is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants' Opinion on Cosmetic Acceptability at End of Treatment</measure>
    <time_frame>At end of treatment, up to 12 weeks</time_frame>
    <description>At the end of treatment, participants provided their opinion on cosmetic acceptability of the investigational product as very good, good, satisfactory, poor, or no opinion. The number of participants in each category of this assessment is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants' Opinion on Practicability of Product Use in Facial Areas Next to the Hairline at End of Treatment</measure>
    <time_frame>At end of treatment, up to 12 weeks</time_frame>
    <description>At the end of treatment, participants provided their opinion on the practicability of the use of the investigational product in facial areas next to the hairline as very good, good, satisfactory, poor, or no opinion. The number of participants in each category of this assessment is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Rosacea Quality of Life (RosaQoL) Questionnaire at End of Treatment - Overall Quality of Life Score</measure>
    <time_frame>Baseline and end of treatment, up to 12 weeks</time_frame>
    <description>The Rosacea Quality of Life (RosaQoL) is a questionnaire to evaluate the effect of rosacea on a participant's quality of life. Each of the 21 items in this questionnaire asks about the frequency with which a particular aspect of living with rosacea affects the participant: possible responses for each item are &quot;never&quot; (score=1), &quot;rarely&quot; (score=2), &quot;sometimes&quot; (score=3), &quot;often&quot; (score=4), or &quot;all the time&quot; (score=5). The overall score is the sum of the results from all 21 questions, with possible scores ranging from 21 (best) to 105 (worst); the higher the score, the more quality of life is impaired. The mean (standard deviation) of the change, defined as end of treatment overall score minus baseline overall score, is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change From Baseline in Dermatology Life Quality Index (DLQI) Questionnaire at End of Treatment - Overall Score</measure>
    <time_frame>Baseline and end of treatment, up to 12 weeks</time_frame>
    <description>The Dermatology Life Quality Index (DLQI) is a questionnaire consisting of a set of 10 questions that evaluate the degree to which the participant's skin has affected certain behaviors and quality of life over the past week. Possible responses to each question are: &quot;very much&quot; (question 7: &quot;yes&quot;) (score=3), &quot;a lot&quot; (score=2), &quot;a little&quot; (score=1), or &quot;not at all&quot;/&quot;not relevant&quot; (score=0). The DLQI overall score is the sum of the results from all 10 questions, with possible scores ranging from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. The number of participants with score changes (end of treatment - baseline) in DLQI overall score from baseline to end of treatment &lt;=-5 and &gt;-5 are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EuroQol Group Questionnaire-Visual Analogue Scale (EQ-VAS) at End of Treatment</measure>
    <time_frame>Baseline and end of treatment, up to 12 weeks</time_frame>
    <description>The EuroQol Group Questionnaire-Visual Analogue Scale (EQ-VAS) is a standardized instrument for use as a measure of health outcome. The EQ-VAS asks for a judgment of the overall health status assessed by the participant her/himself. The 20-cm visual analog scale (VAS) has endpoints labeled &quot;best imaginable health state&quot; and &quot;worst imaginable health state&quot; that are anchored at 100 and 0, respectively. Respondents are asked to indicate how they rate their own health by drawing a line from an anchor box to that point on the EQ-VAS, which best represents their own health on that day; higher scores indicate a better health state. The median (range) of the change, defined as EQ-VAS at end of treatment minus EQ-VAS at baseline, is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Index Value at End of Treatment</measure>
    <time_frame>Baseline and end of treatment, up to 12 weeks</time_frame>
    <description>The EuroQol Group Questionnaire-5 Dimensions-5 Levels (EQ-5D-5L) is a standardized instrument for use as a measure of health outcome. Applicable to a wide range of health conditions and treatments, it provides a simple descriptive profile and a single index value for health status. It is used to assess the level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension is evaluated using 5 levels: &quot;no problems&quot; (level 1), &quot;slight problems&quot; (level 2), &quot;moderate problems&quot; (level 3), &quot;severe problems&quot; (level 4), and &quot;extreme problems&quot; (level 5). A scoring formula developed by EuroQol Group calculates a single index value from the results from all 5 domains along a continuum of 0 (death) to 1 (full health). The median (range) change, defined as the index value at end of treatment minus the index value at baseline, is presented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">961</enrollment>
  <condition>Papulopustular Rosacea</condition>
  <arm_group>
    <arm_group_label>Azelaic acid foam, 15% (BAY39-6251)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle foam</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azelaic acid foam, 15% (BAY39-6251)</intervention_name>
    <description>Azelaic acid twice daily topical application</description>
    <arm_group_label>Azelaic acid foam, 15% (BAY39-6251)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle foam</intervention_name>
    <description>twice daily topical application</description>
    <arm_group_label>Vehicle foam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of papulopustular rosacea

          -  Free of any clinically significant disease, which could interfere with the study

          -  Male or female subject aged ≥ 18 years

          -  Willingness of subject to follow all study procedures

          -  Signed written informed consent before any study-related activities are carried out

        Exclusion Criteria:

          -  Subjects who are known to be non-responders to azelaic acid

          -  Presence of dermatoses that might interfere with rosacea diagnosis

          -  Ocular rosacea; phymatous rosacea; subjects with plaque-type rosacea lesions,
             papulopustular rosacea that requires systemic treatment

          -  Topical use of any prescription or non-prescription medication to treat rosacea within
             6 weeks prior to randomization and throughout the study

          -  Systemic use of any prescription or non-prescription medication to treat rosacea
             (Retinoids within 6 months, Tetracycline within 2 months, Corticosteroids,
             erythromycin, azithromycin, and/or metronidazole within 4 weeks) prior to
             randomization and throughout the study

          -  Facial laser surgery for telangiectasia (or other conditions) within 6 weeks prior to
             randomization

          -  Known hypersensitivity to any ingredients of the investigational product formulation

          -  Participation in another clinical research in parallel or within the last 4 weeks
             before randomization in this study

          -  Any condition or therapy that in the investigator's opinion may pose a risk to the
             subject or that could interfere with any evaluation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33437</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472-2952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Augustine</city>
        <state>Florida</state>
        <zip>32086</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buffalo Grove</city>
        <state>Illinois</state>
        <zip>60089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Kentucky</state>
        <zip>40475</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here and search for websynopsis results provided by Bayer</description>
  </link>
  <results_reference>
    <citation>Draelos ZD, Elewski BE, Harper JC, Sand M, Staedtler G, Nkulikiyinka R, Shakery K. A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea. Cutis. 2015 Jul;96(1):54-61.</citation>
    <PMID>26244354</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2012</study_first_submitted>
  <study_first_submitted_qc>March 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2012</study_first_posted>
  <results_first_submitted>December 28, 2014</results_first_submitted>
  <results_first_submitted_qc>January 25, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 27, 2015</results_first_posted>
  <last_update_submitted>December 28, 2015</last_update_submitted>
  <last_update_submitted_qc>December 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rosacea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azelaic acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Azelaic Acid Foam, 15% (BAY39-6251)</title>
          <description>0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Vehicle Foam</title>
          <description>0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="483"/>
                <participants group_id="P2" count="478"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="419"/>
                <participants group_id="P2" count="399"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="447">Treatment completers and non-completers were asked to participate in the follow-up phase.</participants>
                <participants group_id="P2" count="439">Treatment completers and non-completers were asked to participate in the follow-up phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="409"/>
                <participants group_id="P2" count="394"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Azelaic Acid Foam, 15% (BAY39-6251)</title>
          <description>0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Vehicle Foam</title>
          <description>0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="483"/>
            <count group_id="B2" value="478"/>
            <count group_id="B3" value="961"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.2" spread="12.3"/>
                    <measurement group_id="B2" value="51.9" spread="13.2"/>
                    <measurement group_id="B3" value="51.5" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="354"/>
                    <measurement group_id="B2" value="348"/>
                    <measurement group_id="B3" value="702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Investigator’s Global Assessment (IGA)</title>
          <description>The IGA consists of 5 scores: 1) Clear: no papules and/or pustules; no erythema; 2) Minimal: rare papules and/or pustules; faint up to but not including mild erythema; 3) Mild: few papules and/or pustules; mild erythema; 4) Moderate: pronounced number of papules and/or pustules (but less than numerous papules and/or pustules); moderate erythema; 5) Severe: numerous papules and/or pustules, occasionally with confluent areas of inflamed lesions; moderate to severe erythema.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="418"/>
                    <measurement group_id="B2" value="416"/>
                    <measurement group_id="B3" value="834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion count</title>
          <units>Inflammatory lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.7" spread="9.1"/>
                    <measurement group_id="B2" value="21.2" spread="8.7"/>
                    <measurement group_id="B3" value="21.4" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Erythema rating</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Clear or almost clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="364"/>
                    <measurement group_id="B2" value="370"/>
                    <measurement group_id="B3" value="734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Investigator’s Global Assessment (IGA) Based Therapeutic Success at End of Treatment (LOCF: Last Observation Carried Forward)</title>
        <description>Static evaluation of overall severity of papulopustular rosacea at a given time: 1) Clear: no papules and/or pustules; no erythema; 2) Minimal: rare papules and/or pustules; faint up to but not including mild erythema; 3) Mild: few papules and/or pustules; mild erythema; 4) Moderate: pronounced number of papules and/or pustules (but less than numerous papules and/or pustules); moderate erythema; 5) Severe: numerous papules and/or pustules, occasionally with confluent areas of inflamed lesions; moderate to severe erythema. Therapeutic success is defined as an IGA score of clear or minimal.</description>
        <time_frame>At end of treatment (LOCF), up to 12 weeks</time_frame>
        <population>All subjects who were randomized and who were dispensed any study medication. For subjects with missing end of treatment observation the last non-missing observation was carried forward, including baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid Foam, 15% (BAY39-6251)</title>
            <description>0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Foam</title>
            <description>0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Investigator’s Global Assessment (IGA) Based Therapeutic Success at End of Treatment (LOCF: Last Observation Carried Forward)</title>
          <description>Static evaluation of overall severity of papulopustular rosacea at a given time: 1) Clear: no papules and/or pustules; no erythema; 2) Minimal: rare papules and/or pustules; faint up to but not including mild erythema; 3) Mild: few papules and/or pustules; mild erythema; 4) Moderate: pronounced number of papules and/or pustules (but less than numerous papules and/or pustules); moderate erythema; 5) Severe: numerous papules and/or pustules, occasionally with confluent areas of inflamed lesions; moderate to severe erythema. Therapeutic success is defined as an IGA score of clear or minimal.</description>
          <population>All subjects who were randomized and who were dispensed any study medication. For subjects with missing end of treatment observation the last non-missing observation was carried forward, including baseline.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="483"/>
                <count group_id="O2" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1"/>
                    <measurement group_id="O2" value="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>center-adjusted</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Nominal Change From Baseline in Inflammatory Lesion (IL) Count at End of Treatment (LOCF)</title>
        <description>The mean (standard deviation) change from baseline in the inflammatory lesion count at the end of treatment is provided.</description>
        <time_frame>Baseline and end of treatment (LOCF), up to 12 weeks</time_frame>
        <population>All subjects who were randomized and who were dispensed any study medication. For subjects with missing end of treatment observation the last non-missing observation was carried forward, including baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid Foam, 15% (BAY39-6251)</title>
            <description>0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Foam</title>
            <description>0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Nominal Change From Baseline in Inflammatory Lesion (IL) Count at End of Treatment (LOCF)</title>
          <description>The mean (standard deviation) change from baseline in the inflammatory lesion count at the end of treatment is provided.</description>
          <population>All subjects who were randomized and who were dispensed any study medication. For subjects with missing end of treatment observation the last non-missing observation was carried forward, including baseline.</population>
          <units>Inflammatory lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="483"/>
                <count group_id="O2" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.2" spread="9.5"/>
                    <measurement group_id="O2" value="-10.3" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>ANCOVA</method>
            <method_desc>F-test for treatment effect of the ANCOVA model with treatment group and study center as the factors and baseline lesion count as the covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Inflammatory Lesion Count at End of Treatment (LOCF)</title>
        <description>The mean (standard deviation) percentage change in inflammatory lesion count from baseline to end of study is provided.</description>
        <time_frame>Baseline and end of treatment (LOCF), up to 12 weeks</time_frame>
        <population>All subjects who were randomized and who were dispensed any study medication. For subjects with missing end of treatment observation the last non-missing observation was carried forward, including baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid Foam, 15% (BAY39-6251)</title>
            <description>0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Foam</title>
            <description>0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Inflammatory Lesion Count at End of Treatment (LOCF)</title>
          <description>The mean (standard deviation) percentage change in inflammatory lesion count from baseline to end of study is provided.</description>
          <population>All subjects who were randomized and who were dispensed any study medication. For subjects with missing end of treatment observation the last non-missing observation was carried forward, including baseline.</population>
          <units>Percent change of inflammatory lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="483"/>
                <count group_id="O2" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-61.6" spread="33.5"/>
                    <measurement group_id="O2" value="-50.8" spread="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Investigator’s Global Assessment (IGA) Based Therapeutic Response at End of Treatment (LOCF)</title>
        <description>Participants achieving a clear, minimal, or mild IGA at the end of treatment were considered as ‘responder’. Participants with an IGA of moderate or severe at the end of treatment were considered as ‘non-responder’. Participants who prematurely withdraw from study treatment because of lack of efficacy were coded as ‘non-responders’. The percentage of responders is presented.</description>
        <time_frame>At end of treatment (LOCF), up to 12 weeks</time_frame>
        <population>All subjects who were randomized and who were dispensed any study medication. For subjects with missing end of treatment observation the last non-missing observation was carried forward, including baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid Foam, 15% (BAY39-6251)</title>
            <description>0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Foam</title>
            <description>0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Investigator’s Global Assessment (IGA) Based Therapeutic Response at End of Treatment (LOCF)</title>
          <description>Participants achieving a clear, minimal, or mild IGA at the end of treatment were considered as ‘responder’. Participants with an IGA of moderate or severe at the end of treatment were considered as ‘non-responder’. Participants who prematurely withdraw from study treatment because of lack of efficacy were coded as ‘non-responders’. The percentage of responders is presented.</description>
          <population>All subjects who were randomized and who were dispensed any study medication. For subjects with missing end of treatment observation the last non-missing observation was carried forward, including baseline.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="483"/>
                <count group_id="O2" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.3"/>
                    <measurement group_id="O2" value="54.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Grouped Changes From Baseline in Erythema Intensity Score at End of Treatment (LOCF)</title>
        <description>Erythema was rated as: clear or almost clear; mild; moderate; or severe. For the assessment of the grouped change in erythema ratings, the baseline examination was used to group into ‘improved’, ‘no change’, or ‘worsened’. A participant was considered to have an ‘improved’ erythema rating if the erythema rating was lower compared to the baseline rating, ‘no change’ if the rating was identical, and ‘worsened’ if the rating was higher. The percentage of participants in each of these categories is presented.</description>
        <time_frame>Baseline and end of treatment (LOCF), up to 12 weeks</time_frame>
        <population>All subjects who were randomized and who were dispensed any study medication. For subjects with missing end of treatment observation the last non-missing observation was carried forward, including baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid Foam, 15% (BAY39-6251)</title>
            <description>0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Foam</title>
            <description>0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Grouped Changes From Baseline in Erythema Intensity Score at End of Treatment (LOCF)</title>
          <description>Erythema was rated as: clear or almost clear; mild; moderate; or severe. For the assessment of the grouped change in erythema ratings, the baseline examination was used to group into ‘improved’, ‘no change’, or ‘worsened’. A participant was considered to have an ‘improved’ erythema rating if the erythema rating was lower compared to the baseline rating, ‘no change’ if the rating was identical, and ‘worsened’ if the rating was higher. The percentage of participants in each of these categories is presented.</description>
          <population>All subjects who were randomized and who were dispensed any study medication. For subjects with missing end of treatment observation the last non-missing observation was carried forward, including baseline.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="483"/>
                <count group_id="O2" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5"/>
                    <measurement group_id="O2" value="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9"/>
                    <measurement group_id="O2" value="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Investigator’s Global Assessment (IGA) Scores at End of Treatment (LOCF)</title>
        <description>The IGA consists of 5 scores: 1) Clear: no papules and/or pustules; no erythema; 2) Minimal: rare papules and/or pustules; faint up to but not including mild erythema; 3) Mild: few papules and/or pustules; mild erythema; 4) Moderate: pronounced number of papules and/or pustules (but less than numerous papules and/or pustules); moderate erythema; 5) Severe: numerous papules and/or pustules, occasionally with confluent areas of inflamed lesions; moderate to severe erythema. The percentage of participants with each score at the end of treatment is provided.</description>
        <time_frame>At end of treatment (LOCF), up to 12 weeks</time_frame>
        <population>All subjects who were randomized and who were dispensed any study medication. For subjects with missing end of treatment observation the last non-missing observation was carried forward, including baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid Foam, 15% (BAY39-6251)</title>
            <description>0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Foam</title>
            <description>0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Investigator’s Global Assessment (IGA) Scores at End of Treatment (LOCF)</title>
          <description>The IGA consists of 5 scores: 1) Clear: no papules and/or pustules; no erythema; 2) Minimal: rare papules and/or pustules; faint up to but not including mild erythema; 3) Mild: few papules and/or pustules; mild erythema; 4) Moderate: pronounced number of papules and/or pustules (but less than numerous papules and/or pustules); moderate erythema; 5) Severe: numerous papules and/or pustules, occasionally with confluent areas of inflamed lesions; moderate to severe erythema. The percentage of participants with each score at the end of treatment is provided.</description>
          <population>All subjects who were randomized and who were dispensed any study medication. For subjects with missing end of treatment observation the last non-missing observation was carried forward, including baseline.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="483"/>
                <count group_id="O2" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                    <measurement group_id="O2" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5"/>
                    <measurement group_id="O2" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2"/>
                    <measurement group_id="O2" value="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2"/>
                    <measurement group_id="O2" value="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nominal Value of Inflammatory Lesion Count at End of Treatment (LOCF)</title>
        <description>The mean (standard deviation) lesion count at the end of treatment is provided.</description>
        <time_frame>At end of treatment (LOCF), up to 12 weeks</time_frame>
        <population>All subjects who were randomized and who were dispensed any study medication. For subjects with missing end of treatment observation the last non-missing observation was carried forward, including baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid Foam, 15% (BAY39-6251)</title>
            <description>0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Foam</title>
            <description>0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Nominal Value of Inflammatory Lesion Count at End of Treatment (LOCF)</title>
          <description>The mean (standard deviation) lesion count at the end of treatment is provided.</description>
          <population>All subjects who were randomized and who were dispensed any study medication. For subjects with missing end of treatment observation the last non-missing observation was carried forward, including baseline.</population>
          <units>Inflammatory lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="483"/>
                <count group_id="O2" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="8.9"/>
                    <measurement group_id="O2" value="10.8" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Erythema Intensity Score at End of Treatment (LOCF)</title>
        <description>The percentage of participants in each rating category of erythema (clear or almost clear; mild; moderate; severe) at the end of treatment is provided.</description>
        <time_frame>At end of treatment (LOCF), up to 12 weeks</time_frame>
        <population>All subjects who were randomized and who were dispensed any study medication. For subjects with missing end of treatment observation the last non-missing observation was carried forward, including baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid Foam, 15% (BAY39-6251)</title>
            <description>0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Foam</title>
            <description>0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Erythema Intensity Score at End of Treatment (LOCF)</title>
          <description>The percentage of participants in each rating category of erythema (clear or almost clear; mild; moderate; severe) at the end of treatment is provided.</description>
          <population>All subjects who were randomized and who were dispensed any study medication. For subjects with missing end of treatment observation the last non-missing observation was carried forward, including baseline.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="483"/>
                <count group_id="O2" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clear or almost clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8"/>
                    <measurement group_id="O2" value="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2"/>
                    <measurement group_id="O2" value="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Grouped Changes From Baseline in Telangiectasia Intensity Score at End of Treatment (LOCF)</title>
        <description>Telangiectasia was rated as: no; mild; moderate; or severe. At the end of study, a participant was considered to have an ‘improved’ telangiectasia rating if the telangiectasia rating was lower compared to the baseline rating, ‘no change’ if the rating was identical, and ‘worsened’ if the rating was higher. The percentage of participants in each category is presented.</description>
        <time_frame>Baseline and end of treatment (LOCF), up to 12 weeks</time_frame>
        <population>All subjects who were randomized and who were dispensed any study medication. For subjects with missing end of treatment observation the last non-missing observation was carried forward, including baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid Foam, 15% (BAY39-6251)</title>
            <description>0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Foam</title>
            <description>0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Grouped Changes From Baseline in Telangiectasia Intensity Score at End of Treatment (LOCF)</title>
          <description>Telangiectasia was rated as: no; mild; moderate; or severe. At the end of study, a participant was considered to have an ‘improved’ telangiectasia rating if the telangiectasia rating was lower compared to the baseline rating, ‘no change’ if the rating was identical, and ‘worsened’ if the rating was higher. The percentage of participants in each category is presented.</description>
          <population>All subjects who were randomized and who were dispensed any study medication. For subjects with missing end of treatment observation the last non-missing observation was carried forward, including baseline.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="483"/>
                <count group_id="O2" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3"/>
                    <measurement group_id="O2" value="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.8"/>
                    <measurement group_id="O2" value="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Facial Skin Color Rating at End of Treatment (LOCF)</title>
        <description>Facial skin color (as compared with skin outside the treatment area) was rated as: normal; barely visible skin lightening; mild skin lightening; moderate skin lightening; severe skin lightening. The percentage of participants in each category of facial skin color at the end of study is presented.</description>
        <time_frame>At end of treatment (LOCF), up to 12 weeks</time_frame>
        <population>All subjects who were randomized and who were dispensed any study medication. For subjects with missing end of treatment observation the last non-missing observation was carried forward, including baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid Foam, 15% (BAY39-6251)</title>
            <description>0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Foam</title>
            <description>0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Facial Skin Color Rating at End of Treatment (LOCF)</title>
          <description>Facial skin color (as compared with skin outside the treatment area) was rated as: normal; barely visible skin lightening; mild skin lightening; moderate skin lightening; severe skin lightening. The percentage of participants in each category of facial skin color at the end of study is presented.</description>
          <population>All subjects who were randomized and who were dispensed any study medication. For subjects with missing end of treatment observation the last non-missing observation was carried forward, including baseline.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="483"/>
                <count group_id="O2" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal skin color</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.1"/>
                    <measurement group_id="O2" value="78.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Barely visible skin-lightening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7"/>
                    <measurement group_id="O2" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild skin lightening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate skin lightening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                    <measurement group_id="O2" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe skin lightening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants' Global Assessment of Treatment Response at End of Treatment</title>
        <description>At the end of treatment, participants assessed the change of papulopustular rosacea from baseline (how it looked, felt, appeared to others) as excellent improvement, good improvement, fair improvement, no improvement, or worse. The number of participants in each category of this assessment is presented.</description>
        <time_frame>At end of treatment, up to 12 weeks</time_frame>
        <population>All subjects who were randomized, were dispensed any study medication and had a non-missing observation at end of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid Foam, 15% (BAY39-6251)</title>
            <description>0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Foam</title>
            <description>0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants' Global Assessment of Treatment Response at End of Treatment</title>
          <description>At the end of treatment, participants assessed the change of papulopustular rosacea from baseline (how it looked, felt, appeared to others) as excellent improvement, good improvement, fair improvement, no improvement, or worse. The number of participants in each category of this assessment is presented.</description>
          <population>All subjects who were randomized, were dispensed any study medication and had a non-missing observation at end of treatment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="432"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants' Global Assessment of Tolerability at End of Treatment</title>
        <description>At the end of treatment, participants provided their opinion on local tolerability of the investigational product as excellent, good, acceptable despite minor irritation, less acceptable due to continuous irritation, non-acceptable, or no opinion. The number of participants in each category of this assessment is presented.</description>
        <time_frame>At end of treatment, up to 12 weeks</time_frame>
        <population>All subjects who were randomized, were dispensed any study medication and had a non-missing observation at end of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid Foam, 15% (BAY39-6251)</title>
            <description>0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Foam</title>
            <description>0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants' Global Assessment of Tolerability at End of Treatment</title>
          <description>At the end of treatment, participants provided their opinion on local tolerability of the investigational product as excellent, good, acceptable despite minor irritation, less acceptable due to continuous irritation, non-acceptable, or no opinion. The number of participants in each category of this assessment is presented.</description>
          <population>All subjects who were randomized, were dispensed any study medication and had a non-missing observation at end of treatment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="432"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acceptable despite minor irritation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Less acceptable due to continuous irritation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not acceptable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No opinion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants' Opinion on Cosmetic Acceptability at End of Treatment</title>
        <description>At the end of treatment, participants provided their opinion on cosmetic acceptability of the investigational product as very good, good, satisfactory, poor, or no opinion. The number of participants in each category of this assessment is presented.</description>
        <time_frame>At end of treatment, up to 12 weeks</time_frame>
        <population>All subjects who were randomized, were dispensed any study medication and had a non-missing observation at end of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid Foam, 15% (BAY39-6251)</title>
            <description>0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Foam</title>
            <description>0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants' Opinion on Cosmetic Acceptability at End of Treatment</title>
          <description>At the end of treatment, participants provided their opinion on cosmetic acceptability of the investigational product as very good, good, satisfactory, poor, or no opinion. The number of participants in each category of this assessment is presented.</description>
          <population>All subjects who were randomized, were dispensed any study medication and had a non-missing observation at end of treatment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="432"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176"/>
                    <measurement group_id="O2" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No opinion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants' Opinion on Practicability of Product Use in Facial Areas Next to the Hairline at End of Treatment</title>
        <description>At the end of treatment, participants provided their opinion on the practicability of the use of the investigational product in facial areas next to the hairline as very good, good, satisfactory, poor, or no opinion. The number of participants in each category of this assessment is presented.</description>
        <time_frame>At end of treatment, up to 12 weeks</time_frame>
        <population>All subjects who were randomized, were dispensed any study medication and had a non-missing observation at end of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid Foam, 15% (BAY39-6251)</title>
            <description>0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Foam</title>
            <description>0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants' Opinion on Practicability of Product Use in Facial Areas Next to the Hairline at End of Treatment</title>
          <description>At the end of treatment, participants provided their opinion on the practicability of the use of the investigational product in facial areas next to the hairline as very good, good, satisfactory, poor, or no opinion. The number of participants in each category of this assessment is presented.</description>
          <population>All subjects who were randomized, were dispensed any study medication and had a non-missing observation at end of treatment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="432"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                    <measurement group_id="O2" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No opinion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Rosacea Quality of Life (RosaQoL) Questionnaire at End of Treatment - Overall Quality of Life Score</title>
        <description>The Rosacea Quality of Life (RosaQoL) is a questionnaire to evaluate the effect of rosacea on a participant’s quality of life. Each of the 21 items in this questionnaire asks about the frequency with which a particular aspect of living with rosacea affects the participant: possible responses for each item are “never” (score=1), “rarely” (score=2), “sometimes” (score=3), “often” (score=4), or “all the time” (score=5). The overall score is the sum of the results from all 21 questions, with possible scores ranging from 21 (best) to 105 (worst); the higher the score, the more quality of life is impaired. The mean (standard deviation) of the change, defined as end of treatment overall score minus baseline overall score, is presented.</description>
        <time_frame>Baseline and end of treatment, up to 12 weeks</time_frame>
        <population>All subjects who were randomized, were dispensed any study medication and had a non-missing observation at end of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid Foam, 15% (BAY39-6251)</title>
            <description>0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Foam</title>
            <description>0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rosacea Quality of Life (RosaQoL) Questionnaire at End of Treatment - Overall Quality of Life Score</title>
          <description>The Rosacea Quality of Life (RosaQoL) is a questionnaire to evaluate the effect of rosacea on a participant’s quality of life. Each of the 21 items in this questionnaire asks about the frequency with which a particular aspect of living with rosacea affects the participant: possible responses for each item are “never” (score=1), “rarely” (score=2), “sometimes” (score=3), “often” (score=4), or “all the time” (score=5). The overall score is the sum of the results from all 21 questions, with possible scores ranging from 21 (best) to 105 (worst); the higher the score, the more quality of life is impaired. The mean (standard deviation) of the change, defined as end of treatment overall score minus baseline overall score, is presented.</description>
          <population>All subjects who were randomized, were dispensed any study medication and had a non-missing observation at end of treatment.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="432"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="12.6"/>
                    <measurement group_id="O2" value="-6.4" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change From Baseline in Dermatology Life Quality Index (DLQI) Questionnaire at End of Treatment - Overall Score</title>
        <description>The Dermatology Life Quality Index (DLQI) is a questionnaire consisting of a set of 10 questions that evaluate the degree to which the participant’s skin has affected certain behaviors and quality of life over the past week. Possible responses to each question are: “very much” (question 7: “yes”) (score=3), “a lot” (score=2), “a little” (score=1), or “not at all”/”not relevant” (score=0). The DLQI overall score is the sum of the results from all 10 questions, with possible scores ranging from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. The number of participants with score changes (end of treatment – baseline) in DLQI overall score from baseline to end of treatment &lt;=-5 and &gt;-5 are presented.</description>
        <time_frame>Baseline and end of treatment, up to 12 weeks</time_frame>
        <population>All subjects who were randomized, were dispensed any study medication and had a non-missing observation at end of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid Foam, 15% (BAY39-6251)</title>
            <description>0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Foam</title>
            <description>0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change From Baseline in Dermatology Life Quality Index (DLQI) Questionnaire at End of Treatment - Overall Score</title>
          <description>The Dermatology Life Quality Index (DLQI) is a questionnaire consisting of a set of 10 questions that evaluate the degree to which the participant’s skin has affected certain behaviors and quality of life over the past week. Possible responses to each question are: “very much” (question 7: “yes”) (score=3), “a lot” (score=2), “a little” (score=1), or “not at all”/”not relevant” (score=0). The DLQI overall score is the sum of the results from all 10 questions, with possible scores ranging from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. The number of participants with score changes (end of treatment – baseline) in DLQI overall score from baseline to end of treatment &lt;=-5 and &gt;-5 are presented.</description>
          <population>All subjects who were randomized, were dispensed any study medication and had a non-missing observation at end of treatment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Score change &lt;=-5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score change &gt;-5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328"/>
                    <measurement group_id="O2" value="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EuroQol Group Questionnaire-Visual Analogue Scale (EQ-VAS) at End of Treatment</title>
        <description>The EuroQol Group Questionnaire-Visual Analogue Scale (EQ-VAS) is a standardized instrument for use as a measure of health outcome. The EQ-VAS asks for a judgment of the overall health status assessed by the participant her/himself. The 20-cm visual analog scale (VAS) has endpoints labeled &quot;best imaginable health state&quot; and &quot;worst imaginable health state&quot; that are anchored at 100 and 0, respectively. Respondents are asked to indicate how they rate their own health by drawing a line from an anchor box to that point on the EQ-VAS, which best represents their own health on that day; higher scores indicate a better health state. The median (range) of the change, defined as EQ-VAS at end of treatment minus EQ-VAS at baseline, is presented.</description>
        <time_frame>Baseline and end of treatment, up to 12 weeks</time_frame>
        <population>All subjects who were randomized, were dispensed any study medication and had a non-missing observation at end of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid Foam, 15% (BAY39-6251)</title>
            <description>0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Foam</title>
            <description>0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EuroQol Group Questionnaire-Visual Analogue Scale (EQ-VAS) at End of Treatment</title>
          <description>The EuroQol Group Questionnaire-Visual Analogue Scale (EQ-VAS) is a standardized instrument for use as a measure of health outcome. The EQ-VAS asks for a judgment of the overall health status assessed by the participant her/himself. The 20-cm visual analog scale (VAS) has endpoints labeled &quot;best imaginable health state&quot; and &quot;worst imaginable health state&quot; that are anchored at 100 and 0, respectively. Respondents are asked to indicate how they rate their own health by drawing a line from an anchor box to that point on the EQ-VAS, which best represents their own health on that day; higher scores indicate a better health state. The median (range) of the change, defined as EQ-VAS at end of treatment minus EQ-VAS at baseline, is presented.</description>
          <population>All subjects who were randomized, were dispensed any study medication and had a non-missing observation at end of treatment.</population>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-67" upper_limit="38"/>
                    <measurement group_id="O2" value="0" lower_limit="-60" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Index Value at End of Treatment</title>
        <description>The EuroQol Group Questionnaire–5 Dimensions–5 Levels (EQ-5D-5L) is a standardized instrument for use as a measure of health outcome. Applicable to a wide range of health conditions and treatments, it provides a simple descriptive profile and a single index value for health status. It is used to assess the level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension is evaluated using 5 levels: “no problems” (level 1), “slight problems” (level 2), “moderate problems” (level 3), “severe problems” (level 4), and “extreme problems” (level 5). A scoring formula developed by EuroQol Group calculates a single index value from the results from all 5 domains along a continuum of 0 (death) to 1 (full health). The median (range) change, defined as the index value at end of treatment minus the index value at baseline, is presented.</description>
        <time_frame>Baseline and end of treatment, up to 12 weeks</time_frame>
        <population>All subjects who were randomized, were dispensed any study medication and had a non-missing observation at end of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid Foam, 15% (BAY39-6251)</title>
            <description>0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Foam</title>
            <description>0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Index Value at End of Treatment</title>
          <description>The EuroQol Group Questionnaire–5 Dimensions–5 Levels (EQ-5D-5L) is a standardized instrument for use as a measure of health outcome. Applicable to a wide range of health conditions and treatments, it provides a simple descriptive profile and a single index value for health status. It is used to assess the level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension is evaluated using 5 levels: “no problems” (level 1), “slight problems” (level 2), “moderate problems” (level 3), “severe problems” (level 4), and “extreme problems” (level 5). A scoring formula developed by EuroQol Group calculates a single index value from the results from all 5 domains along a continuum of 0 (death) to 1 (full health). The median (range) change, defined as the index value at end of treatment minus the index value at baseline, is presented.</description>
          <population>All subjects who were randomized, were dispensed any study medication and had a non-missing observation at end of treatment.</population>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-0.410" upper_limit="0.339"/>
                    <measurement group_id="O2" value="0.000" lower_limit="-0.360" upper_limit="0.488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of treatment until end of study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Azelaic Acid Foam, 15% (BAY39-6251)</title>
          <description>0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Vehicle Foam</title>
          <description>0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Accidental death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Eyelid bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Eyelids pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Chapped lips</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Application site dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Application site dryness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="483"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Application site erosion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="483"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Application site exfoliation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Application site hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Application site inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" events="23" subjects_affected="17" subjects_at_risk="483"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Application site paraesthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Application site reaction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Application site scab</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Application site warmth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Mycotic allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="483"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="483"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="483"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Subcutaneous haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Biopsy lip</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Biopsy skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Dysplastic naevus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Pyogenic granuloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="483"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Unintended pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Hand dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Keloid scar</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Morbihan disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Artificial crown procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Shoulder operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
              <event>
                <sub_title>Skin neoplasm excision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="478"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI may publish study results of their own patients only after review/comment by the sponsor. At least 60 days prior to submitting a manuscript to a publisher, a copy of the manuscript will be provided to the sponsor for review. No publication of confidential information shall be made without the sponsor’s prior written consent. The PI agrees to delete any confidential information which would prejudice the securing of adequate intellectual property protection from the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

